Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Bispecific antibodies for R/R AML: ongoing clinical trials

John DiPersio • 1 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia AMG 330 AMG 673 AMV564 Antibodies Flotetuzumab JNJ-63709178 MCLA 117 XmAb14045

Bispecific antibodies are moving from strength to strength, with a multitude in clinical trials. Here, John DiPersio, MD, PhD, of Washington University School of Medicine, Washington, WA, discusses the bispecific antibodies under investigation for relapsed/refractory acute myeloid leukemia (AML), typically targeting CD123, CD33 or CLL1. Prof. DiPersio was speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from John DiPersio

4:02
Identifying the optimal toxic payloads for antibody-based SCT conditioning using SAv-drug conjugates
John DiPersio • 21 Feb 2023
5:08
LBA: CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT
John DiPersio • 21 Feb 2023
4:13
ALL highlights: tisa-cel reinfusion in B-ALL & targeting CD5 and CD7 with CAR-Ts in T-ALL
John DiPersio • 21 Feb 2023
4:19
Advantages & concerns associated with the use of ADC-based conditioning in SCT recipients
John DiPersio • 21 Feb 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals